Is It Too Late To Consider Agilon Health (AGL) After Its Recent 260% Rally?

Simply Wall St.

May 09

Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2634416173"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634416173\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634416173?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-05-09 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634416173","market":"nz","top_or_hot":-1,"title":"Is It Too Late To Consider Agilon Health (AGL) After Its Recent 260% Rally?","media":"Simply Wall St.","content":"<div>\n<p>Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/news/is-it-too-late-to-consider-agilon-health-agl-after-its-recen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Agilon Health (AGL) After Its Recent 260% Rally?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Agilon Health (AGL) After Its Recent 260% Rally?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-09 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/news/is-it-too-late-to-consider-agilon-health-agl-after-its-recen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/news/is-it-too-late-to-consider-agilon-health-agl-after-its-recen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/news/is-it-too-late-to-consider-agilon-health-agl-after-its-recen","article_id":"2634416173","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-agl/agilon-health/news/is-it-too-late-to-consider-agilon-health-agl-after-its-recen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634416173","pubTimestamp":1778337346,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value.\nThe stock last closed at US$60.66, with returns of 117.0% over 7 days, 265.6% over 30 days and 260.2% year to date. The 1 year and 3 year returns stand at negative 24.6% and negative 90.4% respectively.\nThese sharp moves are drawing attention back to agilon health, especially as investors weigh...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","BK4539":"次新股","AGL":"agilon health, inc.","AGL.AU":"AGL ENERGY LTD","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK7136":"复合型公用事业"},"translate_title":"Agilon Health(AGL)最近上涨260%后，现在考虑是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGL":1.5,"DCF":1,"AGL.AU":1.5},"content_text":"Wondering whether agilon health’s recent action has left the stock looking expensive or still potentially mispriced? This article breaks down what the current price might be implying about its value. The stock last closed at US$60.66, with returns of 117.0% over 7 days, 265.6% over 30 days and 260.2% year to date. The 1 year and 3 year returns stand at negative 24.6% and negative 90.4% respectively. These sharp moves are drawing attention back to agilon health, especially as investors weigh the recent price action against a longer history that includes a 5 year return of negative 91.7%. With that mix of short term strength and longer term weakness, the key question is whether the current valuation is now stretched or still reflecting caution. agilon health currently has a valuation score of 3/6, which means it screens as undervalued on half of Simply Wall St’s checks. The next sections will walk through the standard valuation approaches investors often use, before finishing with a way to look at value that goes beyond the usual ratios and models.  Find out why agilon health's -24.6% return over the last year is lagging behind its peers. AdvertisementApproach 1: agilon health Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a stock could be worth today by projecting future cash flows and discounting them back to the present. For agilon health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at a loss of about $90.1 million. Analyst and extrapolated projections move from a projected free cash flow of $104.6 million loss in 2026 to projected positive free cash flow of $36.4 million in 2030, all expressed in US$ and remaining below the billion range. Simply Wall St aggregates these projections, discounts each year’s cash flow, and arrives at an estimated intrinsic value of about $31.84 per share for agilon health. Compared to a recent share price of $60.66, the model implies the stock is about 90.5% above this DCF estimate. This points to a rich valuation on this metric alone. Result: OVERVALUED Our Discounted Cash Flow (DCF) analysis suggests agilon health may be overvalued by 90.5%. Discover 51 high quality undervalued stocks or create your own screener to find better value opportunities. AGL Discounted Cash Flow as at May 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for agilon health. Approach 2: agilon health Price vs Sales (P/S) For companies where earnings are limited or volatile, the P/S ratio can be a useful way to think about value because it compares what investors are paying to the revenue the business generates, rather than to earnings that may be temporarily depressed. In general, higher expected growth and lower perceived risk can justify a higher “normal” P/S multiple, while slower growth and higher risk tend to support a lower multiple. That context helps when you compare a stock’s current P/S to its industry and peers. agilon health currently trades on a P/S ratio of 0.17x. This sits below the Healthcare industry average P/S of 1.21x and below the peer group average of 2.18x. Simply Wall St’s Fair Ratio for agilon health is 0.33x, which is its proprietary estimate of what the P/S could be given factors such as the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics. The Fair Ratio aims to be more tailored than a simple peer or industry comparison because it adjusts for growth, risks, profitability, sector and size, rather than assuming all companies deserve the same multiple. Comparing agilon health’s Fair Ratio of 0.33x with its actual 0.17x P/S suggests the stock screens as undervalued on this measure. Result: UNDERVALUED NYSE:AGL P/S Ratio as at May 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your agilon health Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your own story for agilon health that links what you believe about its future revenue, earnings and margins to a financial forecast, a Fair Value, and then a clear comparison with the current price. All of this is provided within an easy tool on Simply Wall St's Community page that updates when new information like earnings or news arrives. One investor might side with a cautious view closer to a US$6.25 Fair Value, while another leans toward a more optimistic stance nearer US$37.50, and each can see how their assumptions translate into a personal decision-making framework without having to build a full model from scratch. Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying! NYSE:AGL 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}